



**Verena Schoenau**

**Kontakt**

Verena Schoenau

## Publikationen (2)

Borrego-Yaniz G, Ortiz-Fernández L, Madrid-Paredes A, Kerick M, Hernández-Rodríguez J, Mackie S, Vaglio A, Castañeda S, Solans R, Mestre-Torres J, Khalidi N, Langford C, Ytterberg S, Beretta L, Govoni M, Emmi G, Cimmino M, Witte T, Neumann T, Holle J, Schoenau V, Pugnet G, Papo T, Haroche J, Mahr A, Mouthon L, Molberg Ø, Diamantopoulos A, Voskuyl A, Daikeler T, Berger C, Molloy E, Blockmans D, van Sleen Y, Iles M, Sorensen L, Luqmani R, Reynolds G, Bukhari M, Bhagat S, Ortego-Centeno N, Brouwer E, Lamprecht P, Klapa S, Salvarani C, Merkel P, Cid M, González-Gay M, Morgan A, Martin-Broto J, Márquez A, Spanish GCA Group, UK GCA Consortium, Vasculitis Clinical Research Consortium. Risk loci involved in giant cell arteritis susceptibility: a genome-wide association study. *Lancet Rheumatol* 2024; 6:e374-e383.

Rech J, Taşçılar K, Hagen M, Kleyer A, Manger B, Schoenau V, Hueber A, Kleinert S, Baraliakos X, Braun J, Kiltz U, Fleck M, Rubbert-Roth A, Kofler D, Behrens F, Feuchtenberger M, Zaenker M, Voll R, Venhoff N, Thiel J, Glaser C, Feist E, Burmester G, Karberg K, Strunk J, Cañete J, Senolt L, Filkova M, Naredo E, Largo R, Krönke G, D'Agostino M, Østergaard M, Schett G. Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial. *Lancet* 2024; 403:850-859.

## Projekte (0)

Keine Resultate gefunden.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)